{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T07:20:02Z","timestamp":1780384802739,"version":"3.54.1"},"reference-count":72,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Natural killer (NK) cells have proven to be safe and effective immunotherapies, associated with favorable treatment responses in chronic myeloid leukemia (CML). Augmenting NK-cell function with oncological drugs could improve NK-cell\u2013based immunotherapies. Here, we used a high-throughput drug screen consisting of &amp;gt;500 small-molecule compounds, to systematically evaluate the effects of oncological drugs on primary NK cells against CML cells. We identified second mitochondrially derived activator of caspases (SMAC) mimetics as potent enhancers of NK-cell cytotoxicity in both cell lines and primary patient samples. In contrast, several drug classes, including glucocorticoids and tyrosine kinase inhibitors such as dasatinib, inhibited NK-cell cytotoxicity. Single-cell RNA sequencing revealed drug-induced transcriptomic changes in both NK and target CML cells. SMAC mimetics upregulated NF-\u03baB target genes in NK cells, potentially contributing to their enhanced cytotoxicity. Inhibitory drugs dexamethasone, dasatinib, and sotrastaurin prevented NK-cell transition to an activated state and suppressed the expression of interferon gamma (IFN-\u03b3) by NK cells, thus preventing IFN-\u03b3\u2013mediated target cell transcriptomic response. In conclusion, we discovered that SMAC mimetics sensitize cancer cells to NK-cell\u2013mediated killing, with potential clinical applications especially in patients with advanced phase CML.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024025286","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T20:16:11Z","timestamp":1736540171000},"page":"1670-1686","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1723-3970","authenticated-orcid":false,"given":"Petra","family":"Nygr\u00e9n","sequence":"first","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7920-3390","authenticated-orcid":false,"given":"Jonas","family":"Bouhlal","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-6868","authenticated-orcid":false,"given":"Emmi","family":"Jokinen","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4835-3334","authenticated-orcid":false,"given":"Sofia","family":"Forst\u00e9n","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-7966","authenticated-orcid":false,"given":"Essi","family":"Laajala","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7806-8277","authenticated-orcid":false,"given":"Diogo","family":"Dias","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"},{"name":"4Institute for Molecular Medicine Finland, Helsinki Institute of Life Sciences, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6205-7799","authenticated-orcid":false,"given":"Shady","family":"Adnan-Awad","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandr","family":"Ianevski","sequence":"additional","affiliation":[{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"},{"name":"4Institute for Molecular Medicine Finland, Helsinki Institute of Life Sciences, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Klievink","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"L\u00e4hteenm\u00e4ki","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Kuusanm\u00e4ki","sequence":"additional","affiliation":[{"name":"4Institute for Molecular Medicine Finland, Helsinki Institute of Life Sciences, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-7356","authenticated-orcid":false,"given":"Mikko","family":"Myllym\u00e4ki","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5408-1948","authenticated-orcid":false,"given":"Tiina","family":"Kasanen","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9679-683X","authenticated-orcid":false,"given":"Khalid","family":"Saeed","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6693-5392","authenticated-orcid":false,"given":"Dean A.","family":"Lee","sequence":"additional","affiliation":[{"name":"5Division of Hematology, Oncology, and Blood and Marrow Transplant, Nationwide Children's Hospital, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-5696","authenticated-orcid":false,"given":"Henrik","family":"Hjorth-Hansen","sequence":"additional","affiliation":[{"name":"6Department of Hematology, St. Olavs Hospital, Trondheim, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-9769","authenticated-orcid":false,"given":"Tero","family":"Aittokallio","sequence":"additional","affiliation":[{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"},{"name":"4Institute for Molecular Medicine Finland, Helsinki Institute of Life Sciences, University of Helsinki, Helsinki, Finland"},{"name":"7Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway"},{"name":"8Oslo Centre for Biostatistics and Epidemiology, Faculty of Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8084-0282","authenticated-orcid":false,"given":"Olli","family":"Dufva","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-8241","authenticated-orcid":false,"given":"Satu","family":"Mustjoki","sequence":"additional","affiliation":[{"name":"1Hematology Research Unit Helsinki, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland"},{"name":"2Translational Immunology Research Program, University of Helsinki, Helsinki, Finland"},{"name":"3ICAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland"},{"name":"9Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6022","key":"2025041015222651300_bib1","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph' translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"issue":"4","key":"2025041015222651300_bib2","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"2025041015222651300_bib3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"2025041015222651300_bib4","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.5045\/br.2023.2023035","article-title":"Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia","volume":"58","author":"Han","year":"2023","journal-title":"Blood Res"},{"issue":"1","key":"2025041015222651300_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in\u00a0vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"11","key":"2025041015222651300_bib6","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2025041015222651300_bib7","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"J\u00f8rgensen","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2025041015222651300_bib8","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2025041015222651300_bib9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2025041015222651300_bib10","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3324\/haematol.2008.001214","article-title":"Treatment of chronic myeloid leukemia in blast crisis","volume":"93","author":"Hehlmann","year":"2008","journal-title":"Haematologica"},{"issue":"8","key":"2025041015222651300_bib11","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"2025041015222651300_bib12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Adnan Awad","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2025041015222651300_bib13","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","article-title":"Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML","volume":"24","author":"Bj\u00f6rklund","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2025041015222651300_bib14","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2025041015222651300_bib15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","article-title":"Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1\/2 trial","volume":"30","author":"Marin","year":"2024","journal-title":"Nat Med"},{"issue":"17","key":"2025041015222651300_bib16","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.3390\/cancers13174400","article-title":"Cells in myeloproliferative neoplasms (MPN)","volume":"13","author":"Naismith","year":"2021","journal-title":"Cancers"},{"issue":"9","key":"2025041015222651300_bib17","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2025041015222651300_bib18","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"2025041015222651300_bib19","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"2025041015222651300_bib20","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.3389\/fimmu.2018.03152","article-title":"NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia","volume":"9","author":"Chang","year":"2018","journal-title":"Front Immunol"},{"issue":"21","key":"2025041015222651300_bib21","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1182\/blood.V124.21.5508.5508","article-title":"Comparative analysis of NK receptor and T-cell receptor repertoires in patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors","volume":"124","author":"Binotto","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2025041015222651300_bib22","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/leu.2009.46","article-title":"Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy","volume":"23","author":"Mustjoki","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2025041015222651300_bib23","doi-asserted-by":"crossref","first-page":"e1638210","DOI":"10.1080\/2162402X.2019.1638210","article-title":"Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line","volume":"8","author":"Kreutzman","year":"2019","journal-title":"OncoImmunology"},{"issue":"8","key":"2025041015222651300_bib24","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2008-02-138701","article-title":"Dasatinib suppresses in\u00a0vitro natural killer cell cytotoxicity","volume":"111","author":"Blake","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2025041015222651300_bib25","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat Immunol"},{"issue":"12","key":"2025041015222651300_bib26","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","article-title":"Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia","volume":"3","author":"Pemovska","year":"2013","journal-title":"Cancer Discov"},{"issue":"1","key":"2025041015222651300_bib27","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","article-title":"Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations","volume":"40","author":"Letai","year":"2022","journal-title":"Cancer Cell"},{"issue":"9","key":"2025041015222651300_bib28","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019002121","article-title":"Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity","volume":"135","author":"Dufva","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2025041015222651300_bib29","doi-asserted-by":"crossref","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex\u00a0vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"2025041015222651300_bib30","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1093\/bioinformatics\/btaa138","article-title":"Breeze: an integrated quality control and data analysis application for high-throughput drug screening","volume":"36","author":"Potdar","year":"2020","journal-title":"Bioinformatics"},{"key":"2025041015222651300_bib31","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1038\/srep05193","article-title":"Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies","volume":"4","author":"Yadav","year":"2014","journal-title":"Sci Rep"},{"issue":"10","key":"2025041015222651300_bib32","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1007\/s00262-021-02901-y","article-title":"Natural killer cells efficiently target multiple myeloma clonogenic tumor cells","volume":"70","author":"Leivas","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2025041015222651300_bib33","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","article-title":"Comprehensive integration of single-cell data","volume":"177","author":"Stuart","year":"2019","journal-title":"Cell"},{"issue":"1","key":"2025041015222651300_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.pharmthera.2014.05.007","article-title":"Small-molecule SMAC mimetics as new cancer therapeutics","volume":"144","author":"Bai","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"12","key":"2025041015222651300_bib35","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1016\/j.immuni.2023.11.008","article-title":"Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers","volume":"56","author":"Dufva","year":"2023","journal-title":"Immunity"},{"issue":"8","key":"2025041015222651300_bib36","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41590-024-01884-z","article-title":"Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping","volume":"25","author":"Netskar","year":"2024","journal-title":"Nat Immunol"},{"issue":"1","key":"2025041015222651300_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41375-023-02074-w","article-title":"Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation","volume":"38","author":"Huuhtanen","year":"2024","journal-title":"Leukemia"},{"issue":"1-2","key":"2025041015222651300_bib38","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jneuroim.2014.08.618","article-title":"Interleukin-7 expression and its effect on natural killer cells in patients with multiple sclerosis","volume":"276","author":"Su","year":"2014","journal-title":"J\u00a0Neuroimmunol"},{"issue":"7","key":"2025041015222651300_bib39","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ni.3482","article-title":"NK cells and type 1 innate lymphoid cells: partners in host defense","volume":"17","author":"Spits","year":"2016","journal-title":"Nat Immunol"},{"issue":"9","key":"2025041015222651300_bib40","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1084\/jem.20181454","article-title":"NK cells switch from granzyme B to death receptor\u2013mediated cytotoxicity during serial killing","volume":"216","author":"Prager","year":"2019","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"2025041015222651300_bib41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ccr.2007.07.004","article-title":"Frequent engagement of the classical and alternative NF-\u03baB pathways by diverse genetic abnormalities in multiple myeloma","volume":"12","author":"Annunziata","year":"2007","journal-title":"Cancer Cell"},{"issue":"4","key":"2025041015222651300_bib42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1158\/1535-7163.MCT-13-0798","article-title":"Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-\u03baB activation, and is active in patient-derived xenograft models","volume":"13","author":"Benetatos","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2025041015222651300_bib43","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1379\/CSC-32R.1","article-title":"Intronic hormone response elements mediate regulation of FKBP5 by progestins and glucocorticoids","volume":"9","author":"Hubler","year":"2004","journal-title":"Cell Stress Chaperones"},{"issue":"1","key":"2025041015222651300_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/sj.bjc.6606014","article-title":"The role of FKBP5 in cancer aetiology and chemoresistance","volume":"104","author":"Li","year":"2011","journal-title":"Br J Cancer"},{"key":"2025041015222651300_bib45","unstructured":"Tickle\n              T\n            , TiroshI, GeorgescuC, BrownM, HaasB. inferCNV of the Trinity CTAT Project. Broad Institute of MIT and Harvard. 2019. Accessed 13 May 2023. https:\/\/github.com\/broadinstitute\/inferCNV."},{"key":"2025041015222651300_bib46","doi-asserted-by":"crossref","first-page":"14278","DOI":"10.1038\/ncomms14278","article-title":"Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma [published correction appears in Nat Commun. 2018;9:16231]","volume":"8","author":"Beug","year":"2017","journal-title":"Nat Commun"},{"issue":"12","key":"2025041015222651300_bib47","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nm.4229","article-title":"IAP antagonists induce anti-tumor immunity in multiple myeloma","volume":"22","author":"Chesi","year":"2016","journal-title":"Nat Med"},{"issue":"3","key":"2025041015222651300_bib48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cell.2019.06.014","article-title":"Augmenting immunotherapy impact by lowering tumor TNF cytotoxicity threshold","volume":"178","author":"Vredevoogd","year":"2019","journal-title":"Cell"},{"key":"2025041015222651300_bib49","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.omto.2022.11.004","article-title":"The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity","volume":"27","author":"Song","year":"2022","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"2025041015222651300_bib50","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/2326-6066.CIR-18-0428","article-title":"Antagonism of IAPs enhances CAR T-cell efficacy","volume":"7","author":"Michie","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"2025041015222651300_bib51","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1158\/1535-7163.MCT-15-0475","article-title":"A\u00a0phase I study of the SMAC-mimetic birinapant in adults with refractory solid tumors or lymphoma","volume":"14","author":"Amaravadi","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2025041015222651300_bib52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood-2016-09-742049","article-title":"CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression","volume":"129","author":"Tarafdar","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2025041015222651300_bib53","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.molcel.2017.01.022","article-title":"Caspase-8 acts in a non-enzymatic role as a scaffold for assembly of a pro-inflammatory \u201cFADDosome\u201d complex upon TRAIL stimulation","volume":"65","author":"Henry","year":"2017","journal-title":"Mol Cell"},{"issue":"9","key":"2025041015222651300_bib54","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.cell.2022.03.030","article-title":"Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis","volume":"185","author":"Pan","year":"2022","journal-title":"Cell"},{"key":"2025041015222651300_bib55","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"issue":"8","key":"2025041015222651300_bib56","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in\u00a0vivo expansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2025041015222651300_bib57","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2025041015222651300_bib58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jcyt.2020.09.009","article-title":"Cellular immunotherapy with multiple infusions of in\u00a0vitro-expanded haploidentical natural killer cells after autologous transplantation for patients with plasma cell\u00a0myeloma","volume":"23","author":"Tschan-Plessl","year":"2021","journal-title":"Cytotherapy"},{"key":"2025041015222651300_bib59","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front Immunol"},{"issue":"9","key":"2025041015222651300_bib60","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1002\/cam4.1700","article-title":"Interferon gamma in cancer immunotherapy","volume":"7","author":"Ni","year":"2018","journal-title":"Cancer Med"},{"issue":"3","key":"2025041015222651300_bib61","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","article-title":"Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis","volume":"8","author":"Chawla-Sarkar","year":"2003","journal-title":"Apoptosis"},{"issue":"16","key":"2025041015222651300_bib62","doi-asserted-by":"crossref","first-page":"13153","DOI":"10.1074\/jbc.M007646200","article-title":"Interferon \u03b3 (IFN\u03b3) and tumor necrosis factor \u03b1 synergism in ME-180 cervical cancer cell apoptosis and necrosis: IFN\u03b3 inhibits cytpprotective NF-\u03baB through STAT1\/IRF-1 pathways","volume":"276","author":"Suk","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"2025041015222651300_bib63","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-\u03b3: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"J\u00a0Leukoc Biol"},{"issue":"7","key":"2025041015222651300_bib64","first-page":"2487","article-title":"IFN-\u03b3 induces apoptosis in ovarian cancer cells in\u00a0vivo and in\u00a0vitro","volume":"9","author":"Wall","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2025041015222651300_bib65","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","article-title":"Imatinib inhibits T-cell receptor\u2013mediated T-cell proliferation and activation in a dose-dependent manner","volume":"105","author":"Seggewiss","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2025041015222651300_bib66","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","article-title":"Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and\u00a0proliferation","volume":"111","author":"Schade","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2025041015222651300_bib67","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s00262-006-0232-9","article-title":"Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM\/CD168 in\u00a0vitro","volume":"56","author":"Chen","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"2025041015222651300_bib68","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1158\/1078-0432.CCR-07-4393","article-title":"Profound inhibition of antigen-specific T-cell effector functions by dasatinib","volume":"14","author":"Weichsel","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2025041015222651300_bib69","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of dasatinib","volume":"59","author":"Lev\u00eaque","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"2025041015222651300_bib70","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2012.348","article-title":"Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"issue":"15","key":"2025041015222651300_bib71","doi-asserted-by":"crossref","first-page":"6944","DOI":"10.1073\/pnas.90.15.6944","article-title":"Interferon alpha induces protein kinase C-epsilon (PKC-epsilon) gene expression and a 4.7-kb PKC-epsilon-related transcript","volume":"90","author":"Wang","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025041015222651300_bib72","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3389\/fimmu.2012.00187","article-title":"Protein kinase C-\u03b8 (PKC-\u03b8) in natural killer cell function and anti-tumor immunity","volume":"3","author":"Anel","year":"2012","journal-title":"Front Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/15\/1670\/2367983\/blood_bld-2024-025286-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/15\/1670\/2367983\/blood_bld-2024-025286-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T15:22:42Z","timestamp":1744298562000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/15\/1670\/535028\/High-throughput-drug-screening-identifies-SMAC"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":72,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,4,10]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024025286","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]}}}